Department of Endocrinology and Nutrition, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria San Carlos (IdISSC), Facultad de Medicina, Universidad Complutense, C/ Prof. Martin Lagos s/n., Madrid, 28040, Spain,
Obes Surg. 2013 Oct;23(10):1520-6. doi: 10.1007/s11695-013-0995-y.
Controversy exists regarding type 2 diabetes (T2D) remission rates after bariatric surgery (BS) due to heterogeneity in its definition and patients' baseline features. We evaluate T2D remission using recent criteria, according to preoperative characteristics and insulin therapy (IT).
We performed a retrospective study from a cohort of 657 BS from a single center (2006-2011), of which 141 (57.4 % women) had T2D. We evaluated anthropometric and glucose metabolism parameters before surgery and at 1-year follow-up. T2D remission was defined according to 2009 consensus criteria: HbA1c <6%, fasting glucose (FG) <100 mg/dL, and absence of pharmacologic treatment. We analyzed diabetes remission according to previous treatment.
Preoperative characteristic were (mean ± SD): age 53.9 ± 9.8 years, BMI 43.7 ± 5.6 kg/m2, T2D duration 7.4 ± 7.6 years, FG 160.0 ± 54.6 mg/dL, HbA1c 7.6 ± 1.6%. Fifty-six (39.7%) individuals had IT. At 1-year follow-up, 74 patients (52.5%) had diabetes remission. Percentage weight loss (%WL) and percentage excess weight loss (%EWL) were associated to remission (35.5 ± 8.1 vs. 30.2 ± 9.5 %, p = 0.001; 73.6 ± 18.4 vs. 66.3 ± 22.8%, p = 0.037, respectively). Duration of diabetes, age, and female sex were associated to nonremission: 10.3 ± 9.4 vs. 4.7 ± 3.8 years, p < 0.001; 55.1 ± 9.3 vs. 51.2 ± 9.9 years, p = 0.017; 58.9 vs. 33.3%, p = 0.004, respectively. Prior treatment revealed differences in remission rates: 67.1 % in case of oral therapy (OT) vs. 30.4% in IT, p < 0.001. OR for T2D remission in patients with previous IT, compared to those with only OT, were 0.157-0.327 (p < 0.05), adjusting by different models.
Consensus criteria reveal lower T2D remission rates after BS than previously reported. Prior insulin use is a main setback for remission.
由于定义和患者基线特征的异质性,关于减重手术后 2 型糖尿病(T2D)缓解率存在争议。我们根据术前特征和胰岛素治疗(IT)使用最近的标准来评估 T2D 的缓解情况。
我们对来自单一中心(2006-2011 年)的 657 例 BS 队列进行了回顾性研究,其中 141 例(57.4%为女性)患有 T2D。我们评估了手术前和 1 年随访时的人体测量和葡萄糖代谢参数。T2D 缓解根据 2009 年共识标准定义:HbA1c<6%,空腹血糖(FG)<100mg/dL,且无需药物治疗。我们根据先前的治疗方法分析了糖尿病缓解情况。
术前特征为(平均值±标准差):年龄 53.9±9.8 岁,BMI 43.7±5.6kg/m2,T2D 病程 7.4±7.6 年,FG 160.0±54.6mg/dL,HbA1c 7.6±1.6%。56 名(39.7%)患者接受 IT。1 年后,74 名患者(52.5%)糖尿病缓解。体重减轻百分比(%WL)和超重减轻百分比(%EWL)与缓解相关(35.5±8.1% vs. 30.2±9.5%,p=0.001;73.6±18.4% vs. 66.3±22.8%,p=0.037)。糖尿病病程、年龄和女性性别与未缓解相关:10.3±9.4 年 vs. 4.7±3.8 年,p<0.001;55.1±9.3 年 vs. 51.2±9.9 年,p=0.017;58.9% vs. 33.3%,p=0.004)。先前的治疗揭示了缓解率的差异:口服治疗(OT)的缓解率为 67.1%,而 IT 为 30.4%,p<0.001。与仅接受 OT 的患者相比,既往接受 IT 的患者 T2D 缓解的 OR 为 0.157-0.327(p<0.05),通过不同模型进行调整。
共识标准显示减重手术后 T2D 的缓解率低于先前报道。先前使用胰岛素是缓解的主要障碍。